Euretina Logo, Links to homepage.
Euretina Logo, Links to homepage.
  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login
  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login
  • September 10, 2021
  • 2021 Abstracts

Intravitreal aflibercept in routine clinical practice: 12-month results from the French cohort of treatment-naïve patients with macular edema secondary to retinal vein occlusion in the AURIGA study

Author: Audrey Giocanti-Aurégan (France)

Co-authors: Laurent Velasque, Sylvia Nghiem Buffet, Maté Streho, Helmut Allmeier, Tobias Machewitz, Kay D. Rittenhouse

Purpose

The aim of the 24-month AURIGA study is to evaluate the clinical outcomes of intravitreal aflibercept (IVT-AFL) in patients with macular edema secondary to retinal vein occlusion (RVO) or diabetic macular edema (DME) in routine clinical practice. Patients were enrolled from 11 countries, including France. The results of the 12-month analysis in treatment-naïve patients with macular edema secondary to RVO who were enrolled in France are presented here.

Setting/Venue

AURIGA (NCT03161912) is an ongoing, prospective, multicenter, observational study evaluating IVT-AFL in patients with macular edema secondary to RVO or DME. This analysis summarizes the outcomes for the treatment-naïve cohort of patients with RVO in France.

Methods

Treatment-naïve patients (aged ≥18 years) with macular edema secondary to RVO (central RVO [CRVO] and branch RVO [BRVO; also including patients with hemicentral RVO]) were enrolled from April 2018 to January 2019. Decisions regarding IVT-AFL treatment were made at the discretion of the prescribing physician, according to their medical practice. The primary endpoint was the change in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study [ETDRS] letters) from baseline to Month (M)12. Secondary endpoints included the proportion of study eyes with BCVA gains and losses (≥5, ≥10, and ≥15 letters), change in central retinal thickness (CRT) from baseline, number of IVT-AFL injections, mean duration of treatment intervals, and proportion of patients with macular edema on optical coherence tomography. Safety was also evaluated throughout the study. Patients who received at least one IVT-AFL injection and had at least one post-initial observation available were included in the full analysis set.

Results

Of 138 treatment-naïve patients (mean age: 67.7 years; female: 50%; CRVO: n=62; BRVO: n=76), 76% (105/138 patients) completed 1 year of treatment. Overall median duration from diagnosis to IVT-AFL treatment was 0.3 months (range 0–53.5). By M12, mean improvements in BCVA (95% CI) were +13.6 (7.8, 19.3) and +14.6 (11.5, 17.6) letters in CRVO and BRVO patients, respectively (baseline±SD: 41.1±24.1 and 60.6±14.5); 98% of all patients had BCVA decreases <15 letters and 46% had BCVA improvements ≥15 letters. At M12, mean CRT decreased by ‒324.6 (‒388.5, ‒260.8) μm (CRVO; baseline: 672.9±199.7), and ‒232.7 (‒271.3, ‒194.1) μm (BRVO; baseline: 522.8±157.9). The proportion of RVO patients with macular edema decreased from 90% at baseline to 33% at M12. The mean number of IVT-AFL injections was 4.4±1.2 by M6 and 6.6±2.6 by M12 (53% received ≥5 injections by M6; 52% received ≥7 injections by M12). By M12, the last completed treatment interval (for patients who received ≥2 IVT-AFL injections) was ≥10 weeks in 31% (CRVO) and 65% (BRVO) of patients and ≥12 weeks in 21% (CRVO) and 50% (BRVO). Adverse events were consistent with the known safety profile of IVT-AFL. No cases of intraocular inflammation, retinal vasculitis, or endophthalmitis were reported.

Conlusions

In treatment-naïve patients with macular edema secondary to RVO in the AURIGA study, 12-month treatment with IVT-AFL was associated with functional and anatomic improvements in routine clinical practice in France. The magnitude of BCVA gain and CRT improvement at 12 months was comparable to that achieved in interventional studies. No new safety findings were identified. The AURIGA study builds on the wealth of real-world evidence supporting the effectiveness and safety of IVT-AFL as evaluated in 22 published Bayer-sponsored studies in routine clinical practice treating more than 18,000 patients across 24 countries in multiple indications

Financial Disclosure

Audrey Giocanti-Aurégan: Clinical investigator: Bayer Sylvia Nghiem Buffet: Clinical investigator: Bayer Maté Streho: Consultant: Alcon, Bayer, Novartis, and Quantel Medical Laurent Velasque: Consultant: Alcon, Bayer, and Novartis; Clinical investigator: Bayer Agnès Glacet-Bernard: Clinical investigator: Bayer Helmut Allmeier: Employee: Bayer Consumer Care AG, Basel, Switzerland Tobias Machewitz: Employee: Bayer AG, Berlin, Germany Kay D. Rittenhouse: Employee: Bayer Consumer Care AG, Basel, Switzerland Funding: The AURIGA study was funded by Bayer AG, Germany. Medical writing support was provided by ApotheCom, and funded by Bayer Consumer Care AG, Pharmaceuticals, Switzerland.

Comments

Important add below co-authors: 7. - Agnès Glacet-Bernard: Intercommunal Hospital Center and Henri Mondor Hospital, Paris-Est Créteil University (UPEC, Paris XII University), Paris, France
PrevPrevious
NextNext
Euretina Logo, Links to homepage.

European Society of Retina Specialists c/o Congrex Switzerland
Reinacherstrasse 131
4053 Basel
Switzerland

T +41 61 686 77 91
F +41 61 686 77 88

General Enquires: [email protected]

Euretina 2026 Vienna

Ophthalmologica

Forum

Opportunities

Memberships

About

Code of Conduct

Privacy Policy

Contact Us

Euretina 2026 Vienna

Ophthalmologica

Forum

Opportunities

Memberships

About

Code of Conduct

Privacy Policy

Contact Us

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2026 All rights reserved

  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login